Troyanov Stéphan, Wall Catherine A, Miller Judith A, Scholey James W, Cattran Daniel C
Department of Nephrology, University Health Network, Toronto General Hospital, NCSB 11-1256, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada.
J Am Soc Nephrol. 2005 Apr;16(4):1061-8. doi: 10.1681/ASN.2004070593. Epub 2005 Feb 16.
Focal and segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases to terminate in ESRD. A complete remission (CR) confers an excellent long-term prognosis, but the quantitative benefits of partial remissions (PR) have not been defined. This study evaluated the rate of renal function decline (slope of creatinine clearance) and renal survival in nephrotic FSGS patients with CR, PR, or no remission. It also examined relapse rate from remission and its impact on outcome. Multivariate analysis included clinical and laboratory data at presentation and over follow-up, BP control, the agents used, and immunosuppressive therapy. The study cohort was 281 nephrotic FSGS patients who had a minimum of 12 mo of observation and were identified from the Toronto Glomerulonephritis Registry. Over a median follow-up of 65 mo, 55 experienced a CR, 117 had a PR, and 109 had no remission. A PR was independently predictive of slope and survival from renal failure by multivariate analysis (adjusted time-dependent hazard ratio, 0.48; 95% confidence interval, 0.24 to 0.96; P = 0.04). Immunosuppression with high-dose prednisone was associated with a higher rate of PR and CR. Relapse from PR was frequent (56%) and associated with a more rapid rate of renal function decline and worse renal survival compared with relapse-free partial remitters. Only female gender and the nadir of proteinuria during remission were associated with a sustained remission. A PR in proteinuria and its maintenance are important therapeutic targets in FSGS, with implications for both slowing progression rate and improving renal survival.
局灶节段性肾小球硬化(FSGS)是导致终末期肾病(ESRD)的最常见原发性肾小球疾病之一。完全缓解(CR)可带来良好的长期预后,但部分缓解(PR)的量化益处尚未明确。本研究评估了肾病性FSGS患者达到CR、PR或未缓解时的肾功能下降速率(肌酐清除率斜率)和肾脏生存率。还研究了缓解后的复发率及其对预后的影响。多变量分析纳入了就诊时及随访期间的临床和实验室数据、血压控制情况、所用药物以及免疫抑制治疗。研究队列包括281例肾病性FSGS患者,这些患者至少有12个月的观察期,均来自多伦多肾小球肾炎登记处。在中位随访65个月期间,55例达到CR,117例为PR,109例未缓解。多变量分析显示,PR可独立预测肾功能衰竭的斜率和生存率(校正后的时间依赖性风险比为0.48;95%置信区间为0.24至0.96;P = 0.04)。大剂量泼尼松免疫抑制治疗与更高的PR和CR率相关。与无复发的部分缓解者相比,PR后的复发很常见(56%),且与更快的肾功能下降速率和更差的肾脏生存率相关。只有女性性别和缓解期蛋白尿最低点与持续缓解相关。蛋白尿的PR及其维持是FSGS重要的治疗靶点,对减缓疾病进展速率和改善肾脏生存率均有意义。